Bispecific KSI-101 improves barrier tight junctions greater than anti-IL-6 or anti-VEGF monotherapies alone Dual inhibition by KSI-101 confers superior normalization of complex tight junction-mediated barrier biology compared to either anti-VEGF or anti-IL-6 monotherapy alone Demonstrates the synergistic effect of IL-6 and VEGF dual inhibition RPE Cells Vascular Cells B Anti-VEGF Anti-IL-6 KSI-101 Monotherapy Inhibition Dual inhibition No Inhibitors Exogenous VEGF and IL-6 Tight junction disruption and changes in cell morphology RPE cells: nuclei in blue, ZO1 (tight junction protein) in yellow. Red arrows indicate gaps in ZO-1 tight junction protein. Vascular cells: nuclei in purple, ZO1 (tight junction protein) in yellow, actin in green. 59 Kodiak Data on File.